# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a plan...
Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) fa...
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences...
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Cardiol Therapeutics (NASDAQ:CRDL) with a Buy rating an...
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Cardiol Therapeutics (NASDAQ:CRDL) with a Buy rating an...
HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 ...